Company
Boston
Every investor coverage indicates participated in a round Massachusetts General Hospital raised.
Companies Massachusetts General Hospital acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Jagmeet P. Singh | Director (former) | Brandon BioCatalyst, Brandon Capital |
Stories naming Massachusetts General Hospital. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Cardiac pacing company EBR Systems says its SOLVE-CRT trial hit its safety and efficacy goals early, keeping a 2024 US approval bid on course; the article also recalls its 2021 ASX listing.
Opal Therapeutics partners with Massachusetts General Hospital on an HIV immunotherapy collaboration as human trials begin in London; the biotech counts Alloy Ventures, Alta Partners and GBS Ventures among its backers.